Biotech News
Related news
OCSOculis2026-11-16 07:00 EST
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
OCSOculis2026-11-03 21:05 EST
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
KPRXKiora Pharmaceuticals2026-09-08 11:00 EST
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
BLTEBelite Bio2026-08-24 20:00 EST
Belite Bio to Host Virtual Commercial Day on September 2, 2026
OKYOOKYO Pharma2026-07-22 14:00 EST
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
KPRXKiora Pharmaceuticals2026-08-19 11:00 EST
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OKYOOKYO Pharma2026-07-21 13:00 EST
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
BLTEBelite Bio2026-07-15 12:00 EST
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-11-16 07:00 EST
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
OCSOculis2026-11-13 21:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-11-09 07:00 EST
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
OCSOculis2026-11-03 21:05 EST
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
OCSOculis2026-11-02 07:00 EST
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Stock data
- Close
- 7.44 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
